Microbiome identification and bacteriophage formulations
US-2024123002-A1 · Apr 18, 2024 · US
US9347943B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9347943-B2 |
| Application number | US-201013388178-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 26, 2010 |
| Priority date | Aug 28, 2009 |
| Publication date | May 24, 2016 |
| Grant date | May 24, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Chimera proteins including: (i) at least one sequence of a DbpA protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii , and (ii) at least one sequence of an OspC protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii . Also, a method and a kit for the in vitro diagnosis of Lyme borreliosis using said proteins.
Opening claim text (preview).
The invention claimed is: 1. A polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NOs: 8-14. 2. A diagnostic kit comprising the polypeptide as claimed in claim 1 . 3. The diagnostic kit as claimed in claim 2 , further comprising an anti-human-immunoglobulin labeled with a label. 4. The diagnostic kit as claimed in claim 2 , wherein the polypeptide is immobilized on a solid support. 5. The diagnostic kit as claimed in claim 2 , comprising (i) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9, (ii) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 11, and (iii) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 14. 6. The polypeptide as claimed in claim 1 , comprising the amino acid sequence of SEQ ID NO: 8. 7. A diagnostic kit comprising the polypeptide as claimed in claim 6 and an anti-human-immunoglobulin labeled with a label. 8. The polypeptide as claimed in claim 1 , comprising the amino acid sequence of SEQ ID NO: 9. 9. A diagnostic kit comprising the polypeptide as claimed in claim 8 and an anti-human-immunoglobulin labeled with a label. 10. The polypeptide as claimed in claim 1 , comprising the amino acid sequence of SEQ ID NO: 10. 11. A diagnostic kit comprising the polypeptide as claimed in claim 10 and an anti-human-immunoglobulin labeled with a label. 12. The polypeptide as claimed in claim 1 , comprising the amino acid sequence of SEQ ID NO: 11. 13. A diagnostic kit comprising the polypeptide as claimed in claim 12 and an anti-human-immunoglobulin labeled with a label. 14. The polypeptide as claimed in claim 1 , comprising the amino acid sequence of SEQ ID NO: 12. 15. A diagnostic kit comprising the polypeptide as claimed in claim 14 and an anti-human-immunoglobulin labeled with a label. 16. The polypeptide as claimed in claim 1 , comprising the amino acid sequence of SEQ ID NO: 13. 17. A diagnostic kit comprising the polypeptide as claimed in claim 16 and an anti-human-immunoglobulin labeled with a label. 18. The polypeptide as claimed in claim 1 , comprising the amino acid sequence of SEQ ID NO: 14. 19. A diagnostic kit comprising the polypeptide as claimed in claim 18 and an anti-human-immunoglobulin labeled with a label. 20. A method for the in vitro diagnosis of Lyme borreliosis using a biological sample, comprising: bringing the biological sample into contact with at least one polypeptide as claimed in claim 1 ; and determining whether there is formation of an immunological complex between the polypeptide and antibodies of the biological sample. 21. The method as claimed in claim 20 , wherein the antibodies of the biological sample are IgGs and/or IgMs. 22. The method as claimed in claim 21 , wherein the formation of the immunological complex is determined by adding at least one anti-human-immunoglobulin labeled with a label. 23. The method as claimed in claim 20 , wherein the polypeptide is immobilized on a solid support. 24. The method as claimed in claim 21 , wherein the polypeptide is immobilized on a solid support. 25. The method as claimed in claim 22 , wherein the polypeptide is immobilized on a solid support.
Immunostimulants · CPC title
from bacteria · CPC title
from Spirochaetales (O), e.g. Treponema, Leptospira · CPC title
Detection of antibodies in sample from host which are directed against antigens from microorganisms · CPC title
from Spirochaetales (O), e.g. Treponema, Leptospira · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.